| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
|---|---|---|---|---|---|---|
| 2020 | Screening and eradication of Helicobacter pylori for gastric cancer prevention: The Taipei global consensus | Liou J.-M.; Malfertheiner P.; YI-CHIA LEE ; Sheu B.-S.; Sugano K.; Cheng H.-C.; Yeoh K.-G.; Hsu P.-I.; Goh K.-L.; Mahachai V.; Gotoda T.; Chang W.-L.; Chen M.-J.; Chiang T.-H.; Chen C.-C.; Wu C.-Y.; Leow A.H.-R.; Wu J.-Y.; Wu D.-C.; Hong T.-C.; Lu H.; Yamaoka Y.; Megraud F.; Chan F.K.L.; Sung J.J.Y.; Lin J.-T.; Graham D.Y.; Wu M.-S.; El-Omar E.M. | Gut | 56 | ||
| 2010 | Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer | Wu J.-Y.; Shih J.-Y.; Yang C.-H.; Chen K.-Y.; CHAO-CHI HO; Yu C.-J.; Yang P.-C. | International Journal of Cancer | 49 | 41 | |
| 2010 | Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer | Wu J.-Y.; Shih J.-Y.; Yang C.-H.; KUAN-YU CHEN ; Ho C.-C.; Yu C.-J.; Yang P.-C. | International Journal of Cancer | 49 | 41 | |
| 2010 | Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer | Wu J.-Y.; Shih J.-Y.; Yang C.-H.; Chen K.-Y.; Ho C.-C.; Yu C.-J.; PAN-CHYR YANG | International Journal of Cancer | 49 | 41 | |
| 2010 | Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer | Wu J.-Y.; JIN-YUAN SHIH ; Yang C.-H.; Chen K.-Y.; Ho C.-C.; Yu C.-J.; Yang P.-C. | International Journal of Cancer | 47 | 41 | |
| 2010 | Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer | Wu J.-Y.; Shih J.-Y.; Yang C.-H.; Chen K.-Y.; CHAO-CHI HO ; Yu C.-J.; Yang P.-C. | International Journal of Cancer | 47 | 41 | |
| 2010 | Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer | Wu J.-Y.; Shih J.-Y.; Yang C.-H.; Chen K.-Y.; Ho C.-C.; CHONG-JEN YU ; Yang P.-C. | International Journal of Cancer | 47 | 41 | |
| 2016 | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial | Liou J.-M.; CHIEN-CHUAN CHEN ; Chang C.-Y.; Chen M.-J.; CHIEN-CHUAN CHEN ; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium | Gut | 51 | 48 | |
| 2016 | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial | Liou J.-M.; CHIEH-CHANG CHEN ; Chang C.-Y.; Chen M.-J.; CHIEH-CHANG CHEN ; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium | Gut | 51 | 48 | |
| 2016 | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial | Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; CHIA-TUNG SHUN ; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease and Helicobacter Consortium | Gut | 51 | 48 | |
| 2016 | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial | Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; YU-JEN FANG ; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium | Gut | 51 | 48 | |
| 2016 | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial | Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; YI-CHIA LEE ; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium | Gut | 51 | 48 | |
| 2016 | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial | Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; MING-SHIANG WU ; the Taiwan Gastrointestinal Disease; Helicobacter Consortium | Gut | 51 | 48 | |
| 2016 | Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: A randomised trial | JYH-MING LIOU ; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Chen C.-C.; Fang Y.-J.; Lee J.-Y.; Yang T.-H.; Luo J.-C.; Wu J.-Y.; Liou T.-C.; Chang W.-H.; Hsu Y.-C.; Tseng C.-H.; Chang C.-C.; Bair M.-J.; Liu T.-Y.; Hsieh C.-F.; Tsao F.-Y.; Shun C.-T.; Lin J.-T.; Lee Y.-C.; Wu M.-S.; the Taiwan Gastrointestinal Disease; Helicobacter Consortium | Gut | 48 | ||
| 2014 | Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: A systematic review and meta-analysis | Lin K.-H.; Wang F.-L.; Wu M.-S.; Jiang B.-Y.; Kao W.-L.; Chao H.-Y.; Wu J.-Y.; CHIEN-CHANG LEE | Diagnostic Microbiology and Infectious Disease | 63 | 55 | |
| 2014 | Serum procalcitonin and C-reactive protein levels as markers of bacterial infection in patients with liver cirrhosis: A systematic review and meta-analysis | Lin K.-H.; Wang F.-L.; Wu M.-S.; Jiang B.-Y.; Kao W.-L.; Chao H.-Y.; Wu J.-Y.; CHIEN-CHANG LEE | Diagnostic Microbiology and Infectious Disease | 42 | 55 | |
| 2006 | A Single Nucleotide Polymorphism Fine Mapping Study of Chromosome 1q42.1 Reveals the Vulnerability Genes for Schizophrenia, GNPAT and DISC1: Association with Impairment of Sustained Attention | Liu Y.-L.; Fann C.S.-J.; Liu C.-M.; Chen W.J.; Wu J.-Y.; Hung S.-I.; Chen C.-H.; Jou Y.-S.; Liu S.-K.; Hwang T.-J.; MING-HSIEN HSIEH ; Ouyang W.-C.; Chan H.-Y.; Chen J.-J.; Yang W.-C.; Lin C.-Y.; Lee S.F.C.; Hwu H.-G. | Biological Psychiatry | 58 | 52 | |
| 2006 | A Single Nucleotide Polymorphism Fine Mapping Study of Chromosome 1q42.1 Reveals the Vulnerability Genes for Schizophrenia, GNPAT and DISC1: Association with Impairment of Sustained Attention | Liu Y.-L.; Fann C.S.-J.; Liu C.-M.; WEI J. CHEN ; Wu J.-Y.; Hung S.-I.; Chen C.-H.; Jou Y.-S.; Liu S.-K.; Hwang T.-J.; Hsieh M.H.; Ouyang W.-C.; Chan H.-Y.; Chen J.-J.; Yang W.-C.; Lin C.-Y.; Lee S.F.C.; Hwu H.-G. | Biological Psychiatry | 52 | ||
| 2006 | A Single Nucleotide Polymorphism Fine Mapping Study of Chromosome 1q42.1 Reveals the Vulnerability Genes for Schizophrenia, GNPAT and DISC1: Association with Impairment of Sustained Attention | Liu Y.-L.; Fann C.S.-J.; Liu C.-M.; Chen W.J.; Wu J.-Y.; Hung S.-I.; Chen C.-H.; Jou Y.-S.; Liu S.-K.; TZUNG-JENG HWANG ; Hsieh M.H.; Ouyang W.-C.; Chan H.-Y.; Chen J.-J.; Yang W.-C.; Lin C.-Y.; Lee S.F.C.; Hwu H.-G. | Biological Psychiatry | 52 | ||
| 2013 | Systematic review and meta-analysis of the diagnostic accuracy of procalcitonin, C-reactive protein and white blood cell count for suspected acute appendicitis | Yu C.-W.; Juan L.-I.; Wu M.-H.; Shen C.-J.; Wu J.-Y.; CHIEN-CHANG LEE | British Journal of Surgery | 183 | 175 |
